Oxford Cannabinoid Technologies targets a market estimated to be worth over £40 billion by 2027

Proactive Research analyst Ed Stacey presents his analysis on Oxford Cannabinoid Technologies (OCT) is a UK-based pharmaceutical company specialising in drug development from cannabinoids (compounds derived from cannabis). The company aims to become a leader in developing licensed prescription medicines that target the endocannabinoid system with a primary focus on the pain relief market. This […]